Vaccine

RSV (Respiratory Syncytial Virus) Vaccine

This study will measure the immune response to the vaccine.

Ages:

18 - 49

Reimbursement:

up to $300

Trial Length:

Up to 28 days

Qualifications:

  • Healthy Adults ages 18-49

Additional Information

This study will compare 3 lots of the study vaccine, Respiratory Syncytial Virus vaccine (RSV preF).